Company Overview - FTAI Aviation Ltd is under investigation for potential securities law violations following allegations of accounting manipulation in its Maintenance, Repair, and Overhaul (MRO) business [1][5] - The company's shares dropped over 25% after Muddy Waters Research released a report accusing FTAI of misrepresenting whole engine sales as smaller, higher-margin module sales [1] - Muddy Waters Research also claims FTAI inflated EBITDA margins through questionable depreciation methods and engaged in channel stuffing to artificially boost year-end revenue [1] Legal Investigation - Block & Leviton is investigating whether FTAI Aviation committed securities law violations and may file an action to recover losses for affected investors [2][5] - Investors who lost money on FTAI Aviation Ltd common stock may be eligible to join the investigation, regardless of whether they have sold their investment [6] Investor Actions - Investors who suffered losses are advised to contact Block & Leviton to learn more about potential recovery options [3][5] - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors [7] Whistleblower Information - Individuals with non-public information about FTAI Aviation Ltd are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program [4] - Whistleblowers providing original information to the SEC may receive rewards of up to 30% of any successful recovery [4]

Options traders are zeroing in on Barrick Gold Corp (NYSE:GOLD) stock, as the company faces turbulence following the suspension of operations in Mali. The decision comes after the Malian government seized approximately 3 metric tons of gold, valued at $245 million, from the company’s Loulo-Gounkoto mining complex. This action, tied to a dispute over revenue shares owed to the state, underscores escalating military pressure on foreign mining companies as Mali asserts greater control over its mineral resource ...

Kymera Therapeutics, Inc. (KYMR) announced its business goals for 2025, along with anticipated progress on its pipeline of immunology programs.The stock rose 8% on the announcement.Shares of KYMR have surged 47.2% in a year against the industry’s decline of 16%.Image Source: Zacks Investment ResearchKYMR’s Pipeline UpdatesKymera is developing KT-621, an investigational, first-in-class, once-daily oral degrader of STAT6. The candidate has demonstrated dupilumab-like activity and very good safety data in prec ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly (LLY) lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.LLY’s Revised ’24 Sales View Below ExpectationsEli Lilly anticipates fourth-quarter revenues to reach approximately $13.5 billion, bringing the full-year total to $45 billion. However, the reported full-year figure fell short of the company’s previously projected range of $45.4-$46.0 billion shared in October. The reporte ...

  NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Amplify Energy Corp. (NYSE: AMPY), relating to the proposed merger with Juniper Capital. Under the terms of the agreement, Amplify shareholders will retain approximately 61% of Amplify's ou ...

DENVER, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ:BANX) ("ArrowMark Financial"), today announced that BANX's estimated and unaudited Net Asset Value ("NAV") as of December 31, 2024, was $21.80. This estimated NAV is not a comprehensive statement of our financial condition or results for the month December 31, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symb ...

Last year was nothing short of a roller coaster ride for REITs. The commercial real estate sector continued to navigate a generationally difficult market as interest rates continued to rise. Crossing into 2025, rates continue to climb higher and REITsAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ADC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ...

NEW YORK , Jan. 15, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Match Group, Inc. (NASDAQ: MTCH) between May 2, 2023 and November 6, 2024, both dates inclusive (the "Class Period"), of the January 24, 2025 in the securities class action first filed by the Firm.So What: If you purchased Match Group securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

Denali Therapeutics Inc DNLI CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference. The presentation primarily focused on the company’s blood-brain-barrier (BBB) crossing platform technology and the pipeline, including tividenofusp alfa (tivi, DNL310) in Hunter syndrome and DNL126 in Sanfilippo syndrome Type A, as well as ATV:Abeta approach in Alzheimer’s disease.Also Read: Denali Therapeutics’ Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was ExpectedJP Morgan notes th ...

Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.The discussions mainly focused on apitegromab for spinal muscular atrophy (SMA), including its label if approved. They also covered commercial aspects such as the prevalence of SMA, the potential market, and factors influencing its adoption.Also Read: Scholar Rock’s Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next YearRegarding apitegromab in SMA, the company plans to ...